Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (141-150 of 209) with videos related to

Pageof 21
Sort By:
Cancer|April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinomaMartin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.
European Urology|September 4, 2023
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)]Elizabeth R Plimack, Thomas Powles, Viktor Stus, et al.
European Urology Oncology|August 19, 2025
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell CarcinomaCristiane D Bergerot, David Cella, Paulo G Bergerot, et al.
The Journal of Urology|April 7, 2020
Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II TrialDaniel M Geynisman, Brian T Kadow, Brian M Shuch, et al.
The Oncologist|April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract CancerAristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Genitourinary Cancer|December 14, 2020
Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy RegimensOlivia A Do, Lorin A Ferris, Sarah K Holt, et al.
Urologic Oncology|July 15, 2020
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survivalCamilla M Grunewald, Alina Henn, Matthew D Galsky, et al.
The Journal of Urology|July 18, 2018
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial CarcinomaGuru P Sonpavde, Luigi Mariani, Salvatore Lo Vullo, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Pageof 21

Showing results (141-150 of 209) with videos related to

Sort By:
Pageof 21
Cancer|April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinomaMartin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.
European Urology|September 4, 2023
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)]Elizabeth R Plimack, Thomas Powles, Viktor Stus, et al.
European Urology Oncology|August 19, 2025
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell CarcinomaCristiane D Bergerot, David Cella, Paulo G Bergerot, et al.
The Journal of Urology|April 7, 2020
Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II TrialDaniel M Geynisman, Brian T Kadow, Brian M Shuch, et al.
The Oncologist|April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract CancerAristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Genitourinary Cancer|December 14, 2020
Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy RegimensOlivia A Do, Lorin A Ferris, Sarah K Holt, et al.
Urologic Oncology|July 15, 2020
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survivalCamilla M Grunewald, Alina Henn, Matthew D Galsky, et al.
The Journal of Urology|July 18, 2018
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial CarcinomaGuru P Sonpavde, Luigi Mariani, Salvatore Lo Vullo, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Pageof 21